167 related articles for article (PubMed ID: 28166232)
1. Repositioning approved drugs for the treatment of problematic cancers using a screening approach.
Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
PLoS One; 2017; 12(2):e0171052. PubMed ID: 28166232
[TBL] [Abstract][Full Text] [Related]
2. Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis.
Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
PLoS One; 2019; 14(1):e0211268. PubMed ID: 30695050
[TBL] [Abstract][Full Text] [Related]
3. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
Sidarovich V; De Mariano M; Aveic S; Pancher M; Adami V; Gatto P; Pizzini S; Pasini L; Croce M; Parodi F; Cimmino F; Avitabile M; Emionite L; Cilli M; Ferrini S; Pagano A; Capasso M; Quattrone A; Tonini GP; Longo L
Mol Cancer Ther; 2018 Jul; 17(7):1405-1415. PubMed ID: 29695637
[TBL] [Abstract][Full Text] [Related]
4. Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer.
Senkowski W; Zhang X; Olofsson MH; Isacson R; Höglund U; Gustafsson M; Nygren P; Linder S; Larsson R; Fryknäs M
Mol Cancer Ther; 2015 Jun; 14(6):1504-16. PubMed ID: 25911689
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
[TBL] [Abstract][Full Text] [Related]
6. Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma.
Han C; Yu X; Zhang C; Cai Y; Cao Y; Wang S; Shen J
Comb Chem High Throughput Screen; 2019; 22(7):483-495. PubMed ID: 31526347
[TBL] [Abstract][Full Text] [Related]
7. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
Lee H; Kang S; Kim W
PLoS One; 2016; 11(3):e0150460. PubMed ID: 26954019
[TBL] [Abstract][Full Text] [Related]
8. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Investigation of the Role of Benzopyran Dihydropyrimidinone Hybrids in Cell Proliferation, Migration and Tumor Growth.
Dash AK; Nayak D; Hussain N; Mintoo MJ; Bano S; Katoch A; Mondhe DM; Goswami A; Mukherjee D
Anticancer Agents Med Chem; 2019; 19(2):276-288. PubMed ID: 30179143
[TBL] [Abstract][Full Text] [Related]
10. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate.
Cui J; Hollmén M; Li L; Chen Y; Proulx ST; Reker D; Schneider G; Detmar M
Oncotarget; 2017 Jan; 8(1):1007-1022. PubMed ID: 27894093
[TBL] [Abstract][Full Text] [Related]
11. High Throughput Screening for Colorectal Cancer Specific Compounds.
Xie J; Wang C; Gore JC
Comb Chem High Throughput Screen; 2016; 19(3):180-8. PubMed ID: 26830359
[TBL] [Abstract][Full Text] [Related]
12. Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-β-induced cancer-associated fibroblast differentiation.
Coleman DT; Gray AL; Stephens CA; Scott ML; Cardelli JA
Oncotarget; 2016 May; 7(22):32200-9. PubMed ID: 27058757
[TBL] [Abstract][Full Text] [Related]
13. A synergetic screening approach with companion effector for combination therapy: application to retinoblastoma.
Mahida JP; Antczak C; Decarlo D; Champ KG; Francis JH; Marr B; Polans AS; Albert DM; Abramson DH; Djaballah H
PLoS One; 2013; 8(3):e59156. PubMed ID: 23527118
[TBL] [Abstract][Full Text] [Related]
14. Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System.
Laudisi F; Marônek M; Di Grazia A; Monteleone G; Stolfi C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668817
[TBL] [Abstract][Full Text] [Related]
15. Integrating LINCS Data to Evaluate Cancer Transcriptome Modifying Potential of Small-molecule Compounds for Drug Repositioning.
Zhao Y; Liu Y; Bai H
Comb Chem High Throughput Screen; 2021; 24(9):1340-1350. PubMed ID: 33109034
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in drug repositioning for the discovery of new anticancer drugs.
Shim JS; Liu JO
Int J Biol Sci; 2014; 10(7):654-63. PubMed ID: 25013375
[TBL] [Abstract][Full Text] [Related]
17. Revisiting Non-Cancer Drugs for Cancer Therapy.
Yang EJ; Wu C; Liu Y; Lv J; Sup Shim J
Curr Top Med Chem; 2016; 16(19):2144-55. PubMed ID: 26881712
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 2-Substituted 4-Arylidene-5(4H)-oxazolones as Potential Cytotoxic Agents in the Presence of Lemon Juice as a Biocatalyst.
Prasad MG; Lakshmi CV; Katari NK; Anand K; Pal M; Jonnalagadda SB
Comb Chem High Throughput Screen; 2019; 22(9):625-634. PubMed ID: 31696809
[TBL] [Abstract][Full Text] [Related]
19. Anti-Diarrheal Drug Repositioning in Tumour Cell Cytotoxicity.
Elloumi-Mseddi J; Msalbi D; Fakhfakh R; Aifa S
Anticancer Agents Med Chem; 2019; 19(8):1037-1047. PubMed ID: 30657046
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Sampson A; Peterson BG; Tan KW; Iram SH
Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
